AAAAAA
Results:
1-10
|
Results: 10
Authors:
Kern, W
Schleyer, E
Braess, J
Wittmer, E
Ohnesorge, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone [FIS-HAM] salvage therapy in highly resistant acuteleukemias, ANN HEMATOL, 80(6), 2001, pp. 334-339
Authors:
Kern, W
Schoch, C
Haferlach, T
Braess, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Significance of cytogenetic abnormalities, HEMAT BLOOD, 40, 2001, pp. 330-338
Authors:
Feuring-Buske, M
Kneba, M
Unterhalt, M
Engert, A
Gramatzki, M
Hiller, E
Trumper, L
Brugger, W
Ostermann, H
Atzpodien, J
Hallek, M
Aulitzky, E
Hiddemann, W
Citation: M. Feuring-buske et al., IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, ANN HEMATOL, 79(9), 2000, pp. 493-500
Authors:
Feuring-Buske, M
Buske, C
Unterhalt, M
Hiddemann, W
Citation: M. Feuring-buske et al., Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma, ANN HEMATOL, 79(4), 2000, pp. 167-174
Authors:
Kern, W
Schoch, C
Haferlach, T
Braess, J
Unterhalt, M
Wormann, B
Buchner, T
Hiddemann, W
Citation: W. Kern et al., Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities, LEUKEMIA, 14(2), 2000, pp. 226-231
Authors:
Schleyer, E
Rudolph, KL
Braess, J
Unterhalt, M
Ehninger, G
Hiddemann, W
Kern, W
Citation: E. Schleyer et al., Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid, CANC CHEMOT, 45(2), 2000, pp. 165-171
Authors:
Braess, J
Wegendt, C
Jahns-Streubel, G
Kern, W
Keye, S
Unterhalt, M
Schleyer, E
Hiddemann, W
Citation: J. Braess et al., Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine, BR J HAEM, 109(2), 2000, pp. 388-395
Authors:
Buske, C
Feuring-Buske, M
Unterhalt, M
Hiddemann, W
Citation: C. Buske et al., New advances in the treatment of non-Hodgkin lymphoma with monoclonal antibodies, DEUT MED WO, 124(27), 1999, pp. 842-847
Authors:
Buske, C
Feuring-Buske, M
Unterhalt, M
Hiddemann, W
Citation: C. Buske et al., Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy, EUR J CANC, 35(4), 1999, pp. 549-557
Authors:
Wulf, GG
Unterhalt, M
Buchwald, A
Zenker, D
Kreuzer, H
Hiddemann, W
Citation: Gg. Wulf et al., Hypercoagulability in a patient with hypodysfibrinogenemia: Implications for clinical management, ACT HAEMAT, 101(4), 1999, pp. 209-212
Risultati:
1-10
|